title: Evaluation of the efficacy of 50% autologous serum eye drops in different ocular surface pathologies.
abstract: This study evaluated the efficacy of 50% autologous serum eye drops in ocular surface diseases not improved by conventional therapy.
  
  
  
  We analyzed two groups: (1) acute eye pathologies (e.g., chemical burns) and (2) chronic eye pathologies (e.g., recurrent corneal erosion, neurotropic keratitis, and keratoconjunctivitis sicca). The patients were treated for surface instability after conventional therapy. The patients received therapy 5 times a day until stabilization of the framework; they then reduced therapy to 3 times a day for at least 3 months. We analyzed the best corrected visual acuity, epithelial defects, inflammation, corneal opacity, and corneal neovascularization. We also analyzed symptoms such as tearing, burning, sense of foreign body or sand, photophobia, blurred vision, and difficulty opening the eyelids.
  
  
  
  We enrolled 15 eyes in group 1 and 11 eyes in group 2. The average therapy period was 16 ± 5.86 weeks in group 1 and 30.54 ± 20.33 weeks in group 2. The epithelial defects all resolved. Signs and symptoms improved in both groups. In group 2, the defect recurred after the suspension of therapy in 2 (18%) patients; in group 1, no defects recurred.
  
  
  
  Autologous serum eye drops effectively stabilize and improve signs and symptoms in eyes previously treated with conventional therapy.
authors.affiliation: Eye Clinic, Department of Neurological and Vision Sciences, University of Brescia, Piazzale Spedale Civili 1, 25123 Brescia, Italy.
authors.forename: Francesco
authors.identifier: http://orcid.org/0000-0002-2275-4917
authors.initials: F
authors.lastname: Semeraro
authors.affiliation: Eye Clinic, Department of Neurological and Vision Sciences, University of Brescia, Piazzale Spedale Civili 1, 25123 Brescia, Italy.
authors.forename: Eliana
authors.initials: E
authors.lastname: Forbice
authors.affiliation: Eye Clinic, Department of Neurological and Vision Sciences, University of Brescia, Piazzale Spedale Civili 1, 25123 Brescia, Italy.
authors.forename: Osvaldo
authors.identifier: http://orcid.org/0000-0002-6977-9732
authors.initials: O
authors.lastname: Braga
authors.affiliation: Eye Clinic, Department of Neurological and Vision Sciences, University of Brescia, Piazzale Spedale Civili 1, 25123 Brescia, Italy.
authors.forename: Alessandro
authors.identifier: http://orcid.org/0000-0001-6519-2216
authors.initials: A
authors.lastname: Bova
authors.affiliation: Eye Clinic, Department of Neurological and Vision Sciences, University of Brescia, Piazzale Spedale Civili 1, 25123 Brescia, Italy.
authors.forename: Attilio
authors.initials: A
authors.lastname: Di Salvatore
authors.affiliation: Department of Surgical and Morphological Sciences, Section of Ophthalmology, University of Insubria, Ospedale di Circolo, Via F. Guicciardini 9, 21100 Varese, Italy.
authors.forename: Claudio
authors.initials: C
authors.lastname: Azzolini
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003317:Corneal Dystrophies, Hereditary / Q000188:drug therapy* / Q000473:pathology; D019573:Epithelium, Corneal / Q000187:drug effects / Q000473:pathology*; D005260:Female; D006801:Humans; D007634:Keratitis / Q000188:drug therapy* / Q000473:pathology; D007638:Keratoconjunctivitis Sicca / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage* / Q000737:chemistry; D044967:Serum / Q000737:chemistry*; D014792:Visual Acuity / Q000187:drug effects; D014945:Wound Healing / Q000187:drug effects
chemical_list: D009883:Ophthalmic Solutions